Nick Brandon is the chief scientific officer of Neumora Therapeutics, a biotechnology company focused on understanding the complexities of brain disorders and looking to take a precision neuroscience approach to treating them. After completing his PhD and postdoctoral studies in the UK, Dr. Brandon has worked in pharmaceutical or biotechnology companies with the goal of delivering new medicines for disorders of the brain. In that regard, he has been primarily responsible for the discovery of new potential drugs and taking them through the drug development process to make them ready for clinical trials. In positions at Merck, Wyeth, Pfizer, AstraZeneca and now Neumora, he has successfully delivered multiple drug candidates to ‘development candidate’ and IND stages, principally in the areas of neuropsychiatry and neurodegeneration. To date, he has been involved in the nomination of more than 20 drug candidates of which several are still in clinical development.